AI-Driven Metabolic Cohort in Overweight/Obese Chinese Adults
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-60
SponsorZhujiang Hospital
About this trial
The goal of this observational cohort study is to delineate the five-year dynamic trajectories of metabolic phenotypes in Chinese adults with overweight or obesity, with or without type 2 diabetes, focusing on transition rates from metabolically healthy overweight/obesity to unhealthy overweight/obesity or to type 2 diabetes, as well as the incidence and progression of diabetic complications and cardiovascular events in those with type 2 diabetes and overweight/obesity. Researchers will compare three phenotype groups, namely metabolically healthy overweight/obesity, metabolically unhealthy overweight/obesity, and type 2 diabetes with overweight/obesity, to assess differences in metabolic parameter changes, complication rates, and cardiovascular risk. Participants will use a digital health management platform for data upload and lifestyle support, and will complete comprehensive health assessments at baseline, at 2.5 years, and at 5 years, along with annual light follow-ups.
Eligibility criteria
Qualifiers
Able to understand and voluntarily sign the informed consent form, and willing to comply with all study requirements.
Age between 18 and 60 years (inclusive).
Meets at least one of the following overweight/obesity criteria: a) BMI ≥ 24 kg/m²; b) male waist circumference ≥ 90 cm, female waist circumference ≥ 85 cm.
Capable of basic smartphone operation and able to use WeChat or similar communication tools for daily communication.
Disqualifiers
Diagnosis of type 1 diabetes, latent autoimmune diabetes in adults (LADA), maturity-onset diabetes of the young (MODY), or other specific types of diabetes.
Endocrine or metabolic diseases that may affect body weight, including untreated thyroid disorders (hyperthyroidism: TSH < 0.1 mIU/L with FT4 > upper normal limit; hypothyroidism: TSH > 10 mIU/L), Cushing syndrome, acromegaly, polycystic ovary syndrome, or hypopituitarism.
Severe liver disease (Child-Pugh class B or C).
Renal insufficiency (estimated glomerular filtration rate < 30 mL/min/1.73 m²).
Trial design
Treatments tested in this trial
- Not listed
Trial groups
2,800 Participants
are grouped into 3 trial groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov